羚锐制药涨5.01% 产品创新获政策利好资金追捧

智选洞察07-03

羚锐制药股价今日大幅上涨，截至09点38分，最新价为24.30元/股，涨幅达5.01%。产品创新驱动资金聚焦羚锐制药子公司苯环喹溴铵鼻喷雾剂新增感冒适应症于7月1日获批，成为国内首个针对感冒鼻部症状的M受体拮抗剂鼻喷剂。该产品潜在市场规模扩至超50亿元，直接刺激市场做多情绪。截至7月2日，主力资金累计净流入2691万元，推动股价单日上涨5.08%。创新药板块近期受政策利好提振，国家医保局出台支持...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548195847?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-03 09:39","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548195847","market":"sh","top_or_hot":-1,"title":"羚锐制药涨5.01% 产品创新获政策利好资金追捧","media":"智选洞察","content":"<div>\n<p>羚锐制药股价今日大幅上涨，截至09点38分，最新价为24.30元/股，涨幅达5.01%。产品创新驱动资金聚焦羚锐制药子公司苯环喹溴铵鼻喷雾剂新增感冒适应症于7月1日获批，成为国内首个针对感冒鼻部症状的M受体拮抗剂鼻喷剂。该产品潜在市场规模扩至超50亿元，直接刺激市场做多情绪。截至7月2日，主力资金累计净流入2691万元，推动股价单日上涨5.08%。创新药板块近期受政策利好提振，国家医保局出台支持...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703093928a4cc2d2c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>羚锐制药涨5.01% 产品创新获政策利好资金追捧</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n羚锐制药涨5.01% 产品创新获政策利好资金追捧\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-03 09:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703093928a4cc2d2c&s=b><strong>智选洞察</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>羚锐制药股价今日大幅上涨，截至09点38分，最新价为24.30元/股，涨幅达5.01%。产品创新驱动资金聚焦羚锐制药子公司苯环喹溴铵鼻喷雾剂新增感冒适应症于7月1日获批，成为国内首个针对感冒鼻部症状的M受体拮抗剂鼻喷剂。该产品潜在市场规模扩至超50亿元，直接刺激市场做多情绪。截至7月2日，主力资金累计净流入2691万元，推动股价单日上涨5.08%。创新药板块近期受政策利好提振，国家医保局出台支持...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703093928a4cc2d2c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703093928a4cc2d2c&s=b","article_id":"2548195847","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703093928a4cc2d2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548195847","pubTimestamp":1751506763,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"羚锐制药股价今日大幅上涨，截至09点38分，最新价为24.30元/股，涨幅达5.01%。产品创新驱动资金聚焦羚锐制药子公司苯环喹溴铵鼻喷雾剂新增感冒适应症于7月1日获批，成为国内首个针对感冒鼻部症状的M受体拮抗剂鼻喷剂。截至7月2日，主力资金累计净流入2691万元，推动股价单日上涨5.08%。创新药板块近期受政策利好提振，国家医保局出台支持创新药发展措施，年内板块成交额同比增超30%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600285":"羚锐制药","BK0077":"质押式回购","BK0239":"医药制造","BK0070":"员工持股","BK0188":"融资融券"},"translate_title":"Lingrui Pharmaceutical rose 5.01%, product innovation was sought after by favorable policies and funds","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600285":1},"content_text":"羚锐制药股价今日大幅上涨，截至09点38分，最新价为24.30元/股，涨幅达5.01%。产品创新驱动资金聚焦羚锐制药子公司苯环喹溴铵鼻喷雾剂新增感冒适应症于7月1日获批，成为国内首个针对感冒鼻部症状的M受体拮抗剂鼻喷剂。该产品潜在市场规模扩至超50亿元，直接刺激市场做多情绪。截至7月2日，主力资金累计净流入2691万元，推动股价单日上涨5.08%。创新药板块近期受政策利好提振，国家医保局出台支持创新药发展措施，年内板块成交额同比增超30%。尽管中药板块同期微跌，但资金向差异化品种集中，7月2日该股量比达3.70，成交额环比增60%，显示活跃资金博弈意愿强烈。成长动能与估值优势共振新增适应症将覆盖人群从变应性鼻炎扩展至感冒患者，产品已纳入权威诊疗指南，累计研发投入3597万元构筑技术壁垒。公司2024年净利润7.23亿元，同比增27%，近三年营收复合增速超10%。呼吸系统用药市场年复合增长率8%，核心品种有望持续受益行业集中度提升。当前动态市盈率15.89倍，低于医药生物板块中位水平，叠加3.70%股息率，配置性价比凸显。中金公司研报指出，若新适应症商业化顺利，2025年净利润或突破8.5亿元。但需关注集采政策对创新药定价机制的潜在影响，中长期走势将取决于业绩兑现与政策环境匹配度。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548195847","isCrawlerRequest":true}